← Back

TYBR Health

Houston, United States

series-a$30M raisedFreshly fundedMedtechregenerative medicineorthopedics

Total Raised

$30M

Stage

series-a

Location

Houston, United States

Founded

2020

Team size

1-10

Links

About TYBR Health

Houston-based healthtech startup that develops the B3 GEL System, a flowable extracellular matrix hydrogel designed to protect tendons and soft tissue from scarring during orthopedic surgery.

What sets it apart

Its B3 GEL System is a flowable, bioresorbable ECM hydrogel that conforms to complex anatomy and creates a temporary protective barrier during the critical healing window.

Sectors

Medtechregenerative medicineorthopedics

Business

Modelhardware

CustomerOrthopedic surgeons, sports medicine surgeons, and other surgical teams treating tendon, ligament, muscle, and soft-tissue injuries

Notable

  • FDA 510(k) clearance for the B3 GEL System in June 2025
  • First U.S. clinical use of the B3 GEL System announced in January 2026
  • $30 million Series A financing announced in July 2026

Funding rounds

28 Jul 2026

Led by Vensana Capital, Mutual Capital Partners

With Neovate Capital Partners

Source ↗

Explore the market

FAQ

What does TYBR Health do?

Houston-based healthtech startup that develops the B3 GEL System, a flowable extracellular matrix hydrogel designed to protect tendons and soft tissue from scarring during orthopedic surgery.

Where is TYBR Health based?

TYBR Health is based in Houston, United States, founded in 2020.

How much has TYBR Health raised?

TYBR Health has raised $30M in tracked funding and is currently at the series-a stage.

Who has invested in TYBR Health?

Investors in TYBR Health include Vensana Capital, Mutual Capital Partners and Neovate Capital Partners.